Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Book Chapters
, 2022, 'Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy: A Recent Study', in Current Innovations in Medicine and Medical Science Vol. 3, Sciencedomain International, pp. 61 - 87, http://dx.doi.org/10.9734/bpi/cimms/v3/7736f
, 2021, 'Cell-based methods for the identification of Myc-inhibitory small molecules', in The Myc Gene: Methods and Protocols, pp. 337 - 346, http://dx.doi.org/10.1007/978-1-0716-1476-1_19
, 2014, 'Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis', in Efferth T; Bonavida B (ed.), Resistancce to Targeted Anti-Cancer Therapeutics, Springer Press., pp. 27 - 52
, 2013, 'Cell-Based Methods for the Identification of MYC-Inhibitory Small Molecules', in Soucek L; Sodir NM (ed.), The Myc Gene, Humana Press Inc, pp. 255 - 264, http://dx.doi.org/10.1007/978-1-62703-429-6_18
, 2013, 'Oncogene and Cancer - From Bench to Clinic', in Siregar YE; norris (ed.), Oncogene and Cancer - From Bench to Clinic, Inst za onkologiju i radiol, pp. 437 - 454, http://dx.doi.org/10.5772/54813
, 2012, 'Small molecule drugs and targeted therapies for neuroblastoma', in Shimada H (ed.), Neuroblastoma - Present and Future, In Tech, Croatia, pp. 299 - 324, http://www.amazon.com/Neuroblastoma-Present-and-Future-ebook/dp/B00CBWQI92/ref=sr_1_1?ie=UTF8&qid=1366940364&sr=8-1&keywords=neuroblastoma+-+present+and+future#reader_B00CBWQI92
, 2012, 'Targeting Multidrug Resistance in Neuroblastoma', in Hayat MA (ed.), Pediatric Cancer Volume 1 Diagnosis, Therapy and Prognosis: Neuroblastoma, Springer, New York, USA, pp. 115 - 123, http://dx.doi.org/10.1007/978-94-007-2418-1_11
, 2012, 'The Myc Gene: Methods and Protocols: Myc inhibitory molecules', in Methods in Molecular Biology, Humana Press
, 2000, 'Multidrug Resistance Genes in Neuroblastoma', in Neuroblastoma, Elsevier Science BV, Amsterdam, pp. 207 - 215
Journal articles
, 2026, 'Correction: An unexpected role for caspase-2 in neuroblastoma (Cell Death & Disease, (2014), 5, 8, (e1383), 10.1038/cddis.2014.342)', Cell Death and Disease, 17, http://dx.doi.org/10.1038/s41419-026-09023-2
, 2026, 'Precision-guided therapy in H3K27-altered diffuse midline glioma', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-73304-9
, 2026, 'The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-74061-5
, 2026, 'Family experiences of receiving treatment recommendations in a precision medicine trial for poor-prognosis childhood cancer', npj Genomic Medicine, http://dx.doi.org/10.1038/s41525-026-00591-y
, 2026, 'Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young', Molecular Cancer Therapeutics, 25, pp. 1077 - 1094, http://dx.doi.org/10.1158/1535-7163.mct-25-0736
, 2026, 'ID #107 Family experiences of precision-guided treatment recommendations for poor prognosis paediatric Central Nervous System (CNS) cancer', Neuro-Oncology Pediatrics, 2, pp. wuag026.020, http://dx.doi.org/10.1093/neuped/wuag026.020
, 2026, 'ID #736 Ultra-sensitive plasma ctDNA assay enables detection of brain tumour DNA in peripheral blood and is prognostic in childhood brain cancer', Neuro-Oncology Pediatrics, 2, pp. wuag026.309, http://dx.doi.org/10.1093/neuped/wuag026.309
, 2026, 'BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia', British Journal of Haematology, http://dx.doi.org/10.1111/bjh.70598
, 2026, 'Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer', Clinical Cancer Research, 32, pp. 2047 - 2059, http://dx.doi.org/10.1158/1078-0432.CCR-25-3806
, 2026, 'Altering the Diet to Rewire Cancer', New England Journal of Medicine, 394, pp. 1447 - 1450, http://dx.doi.org/10.1056/NEJMcibr2516825
, 2026, 'Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy (Clin Cancer Res, (2021), 27, (1438–1451), 10.1158/1078-0432.CCR-20-3044)', Clinical Cancer Research, 32, pp. 1182, http://dx.doi.org/10.1158/1078-0432.CCR-26-0621
, 2025, 'Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma', Journal of Experimental and Clinical Cancer Research, 44, http://dx.doi.org/10.1186/s13046-025-03502-8
, 2025, 'P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma', Ejc Paediatric Oncology, 6, pp. 100478, http://dx.doi.org/10.1016/j.ejcped.2025.100478
, 2025, 'Data Sharing, Biopsies and Patient Confidentiality in a Precision Medicine Trial for Childhood Cancer: A Mixed Method Study of Parents, Oncologists, and Scientists’ Perspectives', Journal of Personalized Medicine, 15, http://dx.doi.org/10.3390/jpm15110531
, 2025, 'Abstract A001-PR009: Whole-genome-based, tumor-informed circulating tumor DNA detection correlates with treatment response and survival of pediatric solid tumor', Cancer Research, 85, pp. a001-pr009-a001-pr009, http://dx.doi.org/10.1158/1538-7445.pediatric25-a001-pr009
, 2025, 'Abstract A044: The biology of childhood tumors with germline CHEK2 loss of function variants', Cancer Research, 85, pp. a044 - a044, http://dx.doi.org/10.1158/1538-7445.pediatric25-a044
, 2025, 'Abstract A045: Cooperation between germline and somatic drivers in childhood cancer: insights from the ZERO cohort', Cancer Research, 85, pp. a045 - a045, http://dx.doi.org/10.1158/1538-7445.pediatric25-a045
, 2025, 'Immune Response to COVID-19 Vaccination in Children With Cancer', Pediatrics, 156, http://dx.doi.org/10.1542/peds.2024-070209
, 2025, 'Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy', Cancer Research Communications, 5, pp. 1215 - 1227, http://dx.doi.org/10.1158/2767-9764.CRC-25-0080
, 2025, 'Bridging the Gap: Embedding Psychosocial Oncology Research into Comprehensive Cancer Care for Children and Young People', Cancers, 17, pp. 2123 - 2123, http://dx.doi.org/10.3390/cancers17132123
, 2025, 'The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response', Proceedings of the National Academy of Sciences of the United States of America, 122, http://dx.doi.org/10.1073/pnas.2420011122
, 2025, 'The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma', Molecular Oncology, 19, pp. 913 - 936, http://dx.doi.org/10.1002/1878-0261.13789
, 2025, 'Polyamine depletion limits progression of acute leukaemia', International Journal of Cancer, http://dx.doi.org/10.1002/ijc.35362
, 2025, 'Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma', Science Advances, 11, http://dx.doi.org/10.1126/sciadv.ady5599
, 2024, 'Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma', Nature Communications, 15, pp. 10462, http://dx.doi.org/10.1038/s41467-024-54689-x
, 2024, 'Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis', Communications Biology, 7, pp. 1322, http://dx.doi.org/10.1038/s42003-024-06899-8
, 2024, 'The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-45683-4
, 2024, 'The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-49871-0
, 2024, 'Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma', Cancer Medicine, 13, pp. e70082, http://dx.doi.org/10.1002/cam4.70082
, 2024, 'Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing', Nature Structural and Molecular Biology, 31, pp. 1702 - 1716, http://dx.doi.org/10.1038/s41594-024-01336-0
, 2024, 'Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML', Blood, 144, pp. 84 - 98, http://dx.doi.org/10.1182/blood.2024024072
, 2024, 'Precision-guided treatment in high-risk pediatric cancers', Nature Medicine, 30, pp. 1913 - 1922, http://dx.doi.org/10.1038/s41591-024-03044-0
, 2024, 'FDA-approved disulfiram as a novel treatment for aggressive leukemia', Journal of Molecular Medicine, 102, pp. 507 - 519, http://dx.doi.org/10.1007/s00109-023-02414-4
, 2024, 'Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial', British Journal of Cancer, 130, pp. 788 - 797, http://dx.doi.org/10.1038/s41416-023-02525-2
, 2023, 'A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer', Genome Medicine, 15, http://dx.doi.org/10.1186/s13073-023-01170-x
, 2023, 'Abstract B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone', Molecular Cancer Therapeutics, 22, pp. b132 - b132, http://dx.doi.org/10.1158/1535-7163.targ-23-b132
, 2023, 'Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes', Scientific Reports, 13, pp. 3775, http://dx.doi.org/10.1038/s41598-023-30395-4
, 2023, 'Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives', British Journal of Cancer, 129, pp. 1634 - 1644, http://dx.doi.org/10.1038/s41416-023-02429-1
, 2023, 'Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms242115571
, 2023, 'High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer', Cancer Research, 83, pp. 2716 - 2732, http://dx.doi.org/10.1158/0008-5472.CAN-22-3702
, 2023, 'Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial', Journal of Personalized Medicine, 13, http://dx.doi.org/10.3390/jpm13071033